NRIX — Nurix Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.73bn
- $1.68bn
- $83.98m
Nurix Therapeutics gains on agreement with Seagen to develop cancer drugs
Nurix Therapeutics Inc reports results for the quarter ended in May - Earnings Summary
Nurix Therapeutics Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Nurix Therapeutics Presents Data From Studies Of Its Targeted Protein Degraders In B Cell Malignancies
Nurix Therapeutics Inc reports results for the quarter ended in February - Earnings Summary
Brief: Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results
Nurix Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cue Health, Charles Schwab, Semtech
U.S. STOCKS ON THE MOVE-Franchise Group, Connect Biopharma, OSI Systems
Nurix gains as Gilead to license protein degradation drug candidate
Brief: Gilead Exercises Option To License Nurix’S Irak4 Targeted Protein Degrader Development Candidate, Nx-0479
Brief: Nurix Therapeutics - Maintains Operating Account At Svb With Cash Balance Of Less Than 1% Of Co's Total Cash, Cash Equivalents And Marketable Securities
Nurix Therapeutics Inc reports results for the quarter ended in November - Earnings Summary
Brief: Nurix Therapeutics Reports Fourth Quarter, Fiscal Year 2022 Financial Results
Nurix Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview
Nurix Therapeutics gains on FDA clearance for cancer drug trial
Brief: Nurix Therapeutics Announces Clearance Of Investigational New Drug Application For NX-5948 Supporting Plans To Expand Enrollment To U.S. Clinical Sites
Brief: Nurix Therapeutics Presents Positive Clinical Results From Its Novel BTK Degrader (Nx-2127)
Brief: Nurix Therapeutics Reports Case Study Of Patient With Aggressive Non-Hodgkin’S Lymphoma (Nhl) Showing A Complete Clinical Response To Nx-2127 At The 5Th Annual Targeted Protein Degradation (Tpd) Summit